Of those, 23 have buy or overweight ratings. Three have sell or underweight ratings.
The mean target price is just below $198, about 14% above Wednesday’s close.
That target has generally risen in 2023 from around $170 in January.
Two analysts—at Melius Research and Wedbush—have the highest current price targets, at $240. Aletheia Capital, at $125, is the lowest.
